PROGRAMME
ORIGINAL COMMUNICATIONS are invited on any subject relevant to the understanding of diabetes mellitus.
THE CLOSING DATE FOR ABSTRACTS IS 1 APRIL 2010 23:59 hrs CET. Communications must be delivered in English. There is no simultaneous translation. The Provisional Programme will be sent to all paid-up members of EASD in June 2010.
The programme will include the 45th Minkowski Lecture, the 25th Camillo Golgi Lecture, the 42nd Claude Bernard Lecture given by Professor Masato Kasuga, the 4th Albert Renold Prize Lecture for Outstanding Achievement in Research on the Islets of Langerhans, State of the Art Lectures, Symposia and Oral and Poster Presentations.
It is not permitted to take photographs and/or film during any of the sessions.
RECEIPT OF ABSTRACTS
SUBMISSION OF ABSTRACTS
Authors are not permitted to submit work that they know is likely to be published before the EASD Annual Meeting. The Programme Committee has the right to withdraw an abstract from the programme containing material that has already been published. However, EASD will consider abstracts that have been presented in recent months at local or national diabetes meetings. An author submitting or presenting published work will be banned from presenting data at the EASD Meetings for three years.
The box must be marked
stating that the study has been reviewed by the Local Ethics
Committee and that it has therefore been performed in accordance
with the ethical standards laid down in the Helsinki Declaration
(see World
The box must be marked
stating that the study has been carried out along the
“Principles of laboratory animal care” (NIH Publication no.
85-23, revised 1985) and according to the national law, if
applicable.
Selection of
abstracts for the Scientific Programme is made anonymously. THE
ABSTRACT MUST BE SUBMITTED as follows:
Each author can be
listed ONLY ONCE as the presenting author (presenting
author is always the first named author in the author block) on
ONE (1) abstract. Each additional
abstract will be removed from the system before being sent to
the Review Committee. Presenting authors may be
co-authors of other abstracts. It is MANDATORY that the first
named (= presenting) author of any abstract
accepted for presentation be present to deliver his/her paper.
Failure to do so, without prior or adequate explanation sent to
the EASD Office by fax or e-mail, may result in the author or
the institution being banned from presenting abstracts for the
next three years.
The abstract must be
submitted in English. The authors should create an account using
a login name and a password. With this information they can
revise the submission as often as required, make changes,
additions, amendments, change/add/delete authors, copy special
characters easily into the text, re-write the abstract, download
the text from a file or copy it into the submission box. All
this is possible until the Abstract Submission Deadline: 1
April 2010 23:59 hrs CET. After this date the account will
be closed. CHANGES TO THE CONTENT OF THE SUBMITTED ABSTRACT WILL
NOT BE ACCEPTED after the submission deadline.
The abstract
should be submitted in the following way:
1)
The title should be short (maximum 160 characters).
2) Please enter your name and the names of co-authors as given in the following example. It is important to start each name with a capital letter and continue in lower case
Example:
First name:
Last name: Banting
3) The abstract must be
structured. Begin each section with the provided sub-headings in bold (Background and aims:, Materials
and methods:, Results: and Conclusion:). The abstract
structuring words are in the abstract text box (do not change
them or delete them). One or two sentences should describe
the methods, and any aspects of methodology (e.g. use of
control groups, randomisation, patient selection, assay
variation). The sentences stating the results must include hard
data, including statistical analysis.
4)
References are not allowed.
5)
For drugs exclusively generic names should be used (no
trademarks).
6)
A list of approved abbreviations and units of expression
for use without definition
appears in DIABETOLOGIA:
http://www.diabetologia-journal.org/webpages/abbreviations.html
7)
Grant/Support information must be entered into the
special field.
8)
Only one keyword can be selected.
9)
10) A
signed copy of the final version of the abstract must
be sent ONLY per e-mail as PDF file attachment to:
abstracts@easd.org by
5 April 2010 23:59 hrs CET.
KEYWORDS
One keyword from the
list below can be selected for the submission:
02
Genetics of type 1 diabetes
03
Genetics of type 2 diabetes
04
Monogenic forms of diabetes
05
Environmental factors (viruses, nutrients, toxins)
06
Prediction and prevention of type 1 diabetes
07
Prediction of type 2 diabetes
08
Developmental biology, pancreas
09
Stem cells and beta cell generation.
10
Transcriptional regulation and protein synthesis,
pancreas
11
Insulin secretion in vitro and exocytosis
12
Beta cell signal transduction
13
Beta cell damage, degeneration and apoptosis
14
Experimental immunology and animal models of type 1 diabetes
15
Clinical immunology
16
Inflammatory mediators in the pathogenesis of type 1 diabetes
17
Pancreas and islet transplantation
18
Insulin action
19 Insulin sensitivity and resistance
20
Insulin secretion in vivo
21
Hypoglycaemia
22
Gastro-entero pancreatic factors
23
Other hormones
24
Glucose transport
25
Carbohydrate metabolism
26
Protein metabolism
27
Exercise physiology
28
Inflammation in type 2 diabetes
29
Animal models of type 2 diabetes
30
Lipid metabolism
31
Adipose tissue biology and adipocytokines
32
Inflammation in obesity
33
Animal models of obesity
34 Weight regulation and obesity
35
Brain metabolism
36
Diabetes in childhood
37
Nutrition and diet
38
Oral agents – general
39
Incretin based therapies
40
Prevention of type 2 diabetes
41
Insulin therapy
42
Devices
43
Health care delivery
44
Education
45
Psychological aspects
46
Socio-economic aspects
47
Clinical diabetes, other
48
Pregnancy/complications I
49
Neuropathy – somatic
50
Neuropathy – autonomic, incl. erectile dysfunction
51
Diabetic foot and skin disorders
52
Retinopathy
53
Nephropathy
54
Hypertension
55
Cardiac complications
56
Macrovascular disease
57
Pathogenic mechanisms/complications
58
Dyslipidaemia, lipoproteins
59
Endothelium
60
Animal models with complications
61
Other complications
“RISING STAR SYMPOSIUM”
The “Rising Star
Symposium” aims to identify promising and innovative young
researchers who are developing their research activities in
Candidates for the
“Rising Star Symposium” must be paid-up members of EASD and have
a PhD, MD or equivalent degree. The candidates must be under the
age of 38 on 1 January 2010. Preference will be given to
individuals who normally reside in
The application to
deliver a lecture at the “Rising Star Symposium” must
include:
a. A
two-page description of the applicant’s research line, including
supporting references to his/her publications, where
appropriate.
b.
Full name, address, date of birth and brief curriculum vitae of
the applicant (two pages maximum), plus complete list of
publications.
c.
Proof of current EASD membership.
d.
Date and nature of the present appointment held by applicant.
e.
Letter of recommendation from the Head of the Department.
f.
Statement on whether the candidate wishes to apply in
basic or clinical research (the basic and clinical tracks are
evaluated separately).
PROGRAMME COMMITTEE
The Programme Committee
Members will meet in May 2010 and have the absolute right to
accept or reject abstracts. Their decision is final. Only
accepted abstracts will be printed. The Programme Committee’s
decision will be sent in the last week of May 2010 ONLY to the
presenting (= first named) author’s contact e-mail entered in
the online abstract submission tool.
POSTER PRESENTATIONS
Poster presentations
rank equally with oral presentations at EASD Meetings.
Posters must be displayed throughout the Meeting and should be
already mounted in the morning of the first day and removed at
the end of the EASD Meeting. The Posters must be accessible for
study at any time during the hours of the Annual Meeting.
Furthermore, all posters
are presented at special, formal Poster Discussion Sessions
which will be held on Tuesday, Wednesday and Thursday from 12:30
to 14:30, when no other scientific sessions will take place.
These sessions offer an excellent opportunity for direct
scientific exchange. During the Poster Presentation Sessions,
the presenting author must be present or make arrangements for
somebody with knowledge of the displayed work to be present at
the poster. An average of 3 - 5 minutes should be allowed for
each author to present his/her poster to be followed by open
discussion of 3 - 5 minutes (depending on the number of
abstracts in the poster session). Participants can collect a
headset on a first come first serve basis to follow the
presentations within the corresponding sessions. Reprints of the
poster (sheets of DIN A4 format) should be made available.
Detailed instructions will be sent to the presenting author on
notification of acceptance. (ONLY to the presenting (= first
named) author’s contact e-mail entered in the online abstract
submission tool).
PROJECTION FACILITIES
PowerPoint presentation
will be available for Oral Presentations. Instructions on
presentation will be sent to the presenting authors on
notification of acceptance (ONLY to the presenting (=
first named) author’s contact e-mail entered in the online
abstract submission tool). Only single projection is
provided.
VOLUME OF ABSTRACTS
